JP2019214560A - Collyrium composition - Google Patents

Abstract

To provide a collyrium composition that can be directly applied to an eye to wash it.SOLUTION: A collyrium composition is used for washing an eye. It is applied to the eye 3-12 drops at a time.SELECTED DRAWING: None

Description

  The present invention relates to an eyewash composition.

  2. Description of the Related Art Conventionally, an eyecup has been used to wash eyes with an eyewash (for example, Patent Document 1). However, since the eyecup is substantially essential, the scenes where the eyes can be washed with the eyewash are limited, and for example, it has been inconvenient to wash the eyes when going out.

JP 2006-020878 A

  An object of the present invention is to provide an eyewash composition that can wash eyes by direct instillation.

  The present inventor has conducted intensive studies in order to solve the above-mentioned problems, and as a result, found that by applying 3 to 12 drops per time, water-soluble foreign matters and solid foreign matters can be sufficiently removed, and the eyes can be washed. Was. The present invention is based on this finding, and provides the following inventions.

[1]
An eyewash composition for use in washing eyes by applying 3 to 12 drops at a time.
[2]
(A) It contains an antihistamine, the content of the component (A) is 0.00006 to 0.05 w / v% based on the total amount of the eyewash composition, and the pH is 5.0 to 8.5. The eyewash composition according to [1].
[3]
The eyewash composition according to [1] or [2], further comprising (B) a fat-soluble component, and (C) a nonionic surfactant.
[4]
(B) The eyewash composition according to [3], wherein the component is at least one selected from the group consisting of a cooling agent, vitamin E, vitamin A, and oil.
[5]
Component (C) is at least one selected from the group consisting of polyoxyethylene sorbitan fatty acid ester, polyoxyethylene hydrogenated castor oil, polyoxyethylene castor oil, polyoxyethylene polyoxypropylene glycol, and polyethylene glycol monostearate The eyewash composition according to [3], which is:
[6]
The eyewash composition according to [1], comprising a cooling agent and having a pH of 5.0 to 8.5.
[7]
The eyewash composition according to [6], wherein the cooling agent is at least one selected from the group consisting of menthol, camphor, borneol, and geraniol.
[8]
The eyewash composition according to [6], further comprising a nonionic surfactant.
[9]
The nonionic surfactant is at least one selected from the group consisting of polyoxyethylene sorbitan fatty acid ester, polyoxyethylene hydrogenated castor oil, polyoxyethylene castor oil, polyoxyethylene polyoxypropylene glycol, and polyethylene glycol monostearate. The eyewash composition according to [8], which is a seed.
[10]
The eyewash composition according to any one of [1] to [9], which has a viscosity of 1 to 10 mPa · s.
[11]
The eyewash composition according to any one of [1] to [10], wherein at least a part of a portion that comes into contact with the eyewash composition is contained in a container formed of polyethylene.

  ADVANTAGE OF THE INVENTION According to this invention, the eyewash composition which can wash eyes by dropping directly can be provided.

5 is a graph showing a cleaning effect on a water-soluble foreign substance (trypan blue) after performing eye washing with eye drops or eye washing with an eye cup in Test Example 1. 10 is a graph showing the effect of washing solid foreign substances (polystyrene beads) after eye washing with eye drops or eye washing with an eye cup in Test Example 2. 9 is a graph showing a cleaning effect on solid foreign matter (polystyrene beads) after performing eye washing with eye drops when wearing a soft contact lens in Test Example 3. In Test Example 4, it is a graph which shows the stability improvement rate of chlorpheniramine maleate in each eyewash composition of Examples 1-8. In Test Example 4, it is a graph which shows the stability improvement rate of chlorpheniramine maleate in each eyewash composition of Examples 9-11. 13 is a graph showing the evaluation (wash score) of the effect of a cooling agent on the feeling of washing during eye washing in Test Example 5.

  Hereinafter, embodiments for carrying out the present invention will be described in detail. However, the present invention is not limited to the following embodiments.

  In this specification, the unit “%” of the content means “w / v%” and is synonymous with “g / 100 mL” unless otherwise specified.

[1. Eyewash composition)
The eyewash composition according to the present embodiment is used by applying 3 to 12 drops at a time.

  When instilling the eyewash composition according to the present embodiment, the number of drops per time may be 3 to 12 drops, but from the viewpoint that the effect of the present invention is more remarkably exhibited, 4 to 12 drops. Preferably, it is 4 to 9 drops, more preferably 4 to 6 drops.

  When instilling the eyewash composition according to the present embodiment, the drop amount per drop is not particularly limited as long as the drop amount exerts the effect of the present invention, but from the viewpoint that the effect of the present invention is more remarkably exhibited. , Preferably 5 to 100 μL, more preferably 10 to 80 μL, even more preferably 20 to 60 μL, and even more preferably 30 to 50 μL. The amount of each droplet can be adjusted by appropriately setting the material of the container, the area of the opening of the inner plug (nozzle) or the spout, the thickness of the container body, and the compressive strength of the peripheral surface. .

  The eyewash composition according to the present embodiment preferably contains (A) an antihistamine (also simply referred to as “component (A)”). When the eyewash composition contains the component (A), the effect of the present invention is more remarkably exhibited.

[Component (A)]
The antihistamine is a compound having an antihistamine action, and a salt thereof. The antihistamine is not particularly limited as long as it is pharmaceutically, pharmacologically (pharmaceutically) or physiologically acceptable.

  Specific examples of the antihistamine include chlorpheniramine, iproheptin, diphenhydramine, ketotifen, olopatadine, levocabastine, and salts thereof. As the antihistamine, chlorpheniramine and its salts, diphenhydramine and its salts are preferable, chlorpheniramine maleate and diphenhydramine hydrochloride are more preferable, and chlorpheniramine maleate is further preferable.

  A commercially available antihistamine may be used. One kind of the antihistamine may be used alone, or two or more kinds thereof may be used in combination.

  The content of the component (A) in the eyewash composition according to the present embodiment is not particularly limited, and the type of the component (A), the type and content of other compounding components, the use and the formulation of the eyewash composition, and the like. Is set as appropriate according to. As the content of the component (A), from the viewpoint of more remarkably exerting the effects of the present invention, for example, the total content of the component (A) is 0.00006 to 0. It is preferably 0.05 w / v%, more preferably 0.0001 to 0.01 w / v%, and still more preferably 0.0006 to 0.005 w / v%.

  The pH of the eyewash composition according to the present embodiment is preferably 5.0 to 8.5 in view of the stability of the component (A) (particularly, chlorpheniramine and a salt thereof), and is preferably 5.0 to 8.5. It is more preferably 8.0, further preferably 5.0 to 7.5, still more preferably 5.0 to 7.0, and still more preferably 5.0 to 6.5. Particularly preferred.

  The pH of the eyewash composition according to this embodiment can be adjusted using a pH adjuster as needed. Examples of the pH regulator include inorganic acids such as hydrochloric acid, sulfuric acid, phosphoric acid and boric acid; organic acids such as acetic acid and citric acid; inorganic bases such as sodium hydroxide, potassium hydroxide, calcium hydroxide and magnesium hydroxide; Organic bases such as amines and diisopropanolamine; sodium phosphate, disodium hydrogen phosphate, sodium dihydrogen phosphate, potassium phosphate, dipotassium hydrogen phosphate, potassium dihydrogen phosphate, sodium acetate, sodium citrate, carbonic acid Salts of weak acids and strong bases such as sodium, sodium bicarbonate, borax and the like; salts of strong acids and weak bases such as zinc chloride and zinc sulfate.

  The eyewash composition according to the present embodiment is (B) a fat-soluble component (also simply referred to as “(B) component”) in view of the stability of the component (A) (particularly, chlorpheniramine and a salt thereof). And (C) a nonionic surfactant (also simply referred to as “component (C)”). When the eyewash composition contains the component (B) and the component (C), the effects of the present invention are more remarkably exhibited.

  When the component (B) and the component (C) are contained, the stabilizing effect of the component (A) (particularly chlorpheniramine and its salt) is more remarkable as the pH of the eyewash composition according to the present embodiment. From the viewpoint of performance, it is preferably from 6.5 to 8.5, more preferably from 7.0 to 8.5, and still more preferably from 7.5 to 8.5.

[(B) component]
The fat-soluble component is a component having low affinity for water molecules. The fat-soluble component is not particularly limited as long as it is pharmaceutically, pharmacologically (pharmaceutically) or physiologically acceptable.

  Examples of the fat-soluble component include a cooling agent, vitamin E, vitamin A, and oil.

  Specific examples of the cooling agent include menthol, menthol, camphor, borneol, geraniol, cineol, citronellol, carvone, anethole, eugenol, limonene, linalool, linalyl acetate, thymol, cimene, terpineol, pinene, camphene, isoborneol, phenene Chen, nerol, myrcene, myrsenol, linalool acetate, lavandulol, eucalyptus oil, bergamot oil, peppermint oil, cool mint oil, spearmint oil, peppermint oil, fennel oil, cinnamon oil, rose oil, camphor oil. As a cooling agent, menthol, camphor, borneol, geraniol, eucalyptus oil, peppermint oil and peppermint oil are preferred, menthol, camphor, borneol and geraniol are more preferred, and menthol is even more preferred.

  Vitamin E includes tocopherol and its derivatives. Specific examples of tocopherol derivatives include tocopherol acetate, tocopherol succinate, and tocopherol nicotinate. As the vitamin E, a tocopherol derivative is preferable, and tocopherol acetate is more preferable.

  Vitamin A includes retinol and its derivatives. Specific examples of the retinol derivative include retinol palmitate, retinol acetate, retinal, and retinoic acid. Vitamin A is preferably a retinol derivative, more preferably retinol palmitate or retinol acetate, and even more preferably retinol palmitate.

  Oils include vegetable oils, animal oils and mineral oils. Specific examples of vegetable oils include sesame oil, castor oil, olive oil, soybean oil, peanut oil, almond oil, wheat germ oil, camellia oil, corn oil, rapeseed oil, sunflower oil, cottonseed oil, and coconut oil. Specific examples of animal oils include squalane. Mineral oils include liquid paraffin and petrolatum. As the oil, vegetable oil is preferred, sesame oil and castor oil are more preferred, and sesame oil is even more preferred.

  A commercially available fat-soluble component may be used. One fat-soluble component may be used alone, or two or more fat-soluble components may be used in combination.

  The content of the component (B) in the eyewash composition according to the present embodiment is not particularly limited, and the type of the component (B), the type and content of other components, the use and the formulation of the eyewash composition, and the like. Is set as appropriate according to. As the content of the component (B), from the viewpoint of more remarkably exhibiting the effects of the present invention, for example, the total content of the component (B) is 0.00003 to 0. It is preferably 5 w / v%, more preferably 0.00006 to 0.1 w / v%, and even more preferably 0.0003 to 0.05 w / v%. When the component (B) is vitamin A, the total content of vitamin A is preferably from 50 to 50,000 IU, more preferably from 100 to 10,000 IU, and more preferably from 500 to 50,000 IU, based on the total amount of the eyewash composition. More preferably, it is ０００5000 IU.

  In the eyewash composition according to the present embodiment, the content ratio of the component (B) to the component (A) is not particularly limited, and the types of the components (A) and (B), and the types and contents of other compounding components. It is set as appropriate according to the use and formulation of the eyewash composition. As the content ratio of the component (B) to the component (A), for example, from the viewpoint of further enhancing the effect of the present invention, for example, the total content of the component (A) contained in the eyewash composition according to the present embodiment is 1% by mass. Parts, the total content of the component (B) is preferably 0.001 to 50 parts by mass, more preferably 0.01 to 30 parts by mass, and 0.1 to 10 parts by mass. More preferably, it is.

[(C) component]
The nonionic surfactant is a surfactant that does not have a group that dissociates into ions. The nonionic surfactant is not particularly limited as long as it is pharmaceutically, pharmacologically (pharmaceutically) or physiologically acceptable.

  Specific examples of the nonionic surfactant include POE (20) sorbitan monolaurate (polysorbate 20), POE (20) sorbitan monopalmitate (polysorbate 40), POE (20) monostearate sorbitan (polysorbate 60) and trisorbate. POE sorbitan fatty acid esters such as POE (20) sorbitan stearate (polysorbate 65), POE (20) sorbitan monooleate (polysorbate 80); POE (5) hydrogenated castor oil (polyoxyethylene hydrogenated castor oil 5), POE (10) hydrogenated castor oil (polyoxyethylene hydrogenated castor oil 10), POE (20) hydrogenated castor oil (polyoxyethylene hydrogenated castor oil 20), POE (30) hydrogenated castor oil (polyoxyethylene hydrogenated castor oil 30), POE (40) curing Castor oil (polyoxyethylene hydrogenated castor oil 40), POE (60) hydrogenated castor oil (polyoxyethylene hydrogenated castor oil 60), POE (80) hydrogenated castor oil (polyoxyethylene hydrogenated castor oil 80), POE (100) POE hardened castor oil such as hardened castor oil (polyoxyethylene hardened castor oil 100); POE (3) castor oil (polyoxyethylene castor oil 3), POE (10) castor oil (polyoxyethylene castor oil 10), POE (35) POE castor oil such as castor oil (polyoxyethylene castor oil 35), POE (70) castor oil (polyoxyethylene castor oil 70); POE (9) POE alkyl ether such as lauryl ether; POE (20) POE (4) POE-POP alkyl ether such as cetyl ether; POE (20) P P (20) glycol (Pluronic L44), POE (42) POP (67) glycol (Poloxamer 403, Pluronic P123), POE (54) POP (39) glycol (Poloxamer 235, Pluronic P85), POE (120) POP ( 40) Glycol (Pluronic F87), POE (160) POP (30) Glycol (Poloxamer 188, Pluronic F68), POE (196) POP (67) Glycol (Poloxamer 407, Pluronic F127), POE (200) POP (70) POE / POP glycols such as glycol; and polyethylene glycol monostearate such as polyoxyl stearate 10 and polyoxyl stearate 40. In the compounds exemplified above, the numbers in parentheses indicate the number of moles added. The abbreviation "POE" means polyoxyethylene, and the abbreviation "POP" means polyoxypropylene. As nonionic surfactants, POE sorbitan fatty acid esters, POE hydrogenated castor oil, POE castor oil, POE POP glycol, polyethylene glycol monostearate are preferred, and polysorbate 80, polyoxyethylene hydrogenated castor oil 60, and poloxamer 407 are preferred. More preferred are polysorbate 80 and polyoxyethylene hydrogenated castor oil 60.

  A commercially available nonionic surfactant may be used. As the nonionic surfactant, one type may be used alone, or two or more types may be used in combination.

  The content of the component (C) in the eyewash composition according to the present embodiment is not particularly limited, and the type of the component (C), the type and content of other compounding components, the use and the formulation of the eyewash composition, and the like. Is set as appropriate according to. As the content of the component (C), from the viewpoint of more remarkably exerting the effects of the present invention, for example, the total content of the component (C) is 0.01 to 10 w /, based on the total amount of the eyewash composition. v%, more preferably 0.01 to 5 w / v%, even more preferably 0.01 to 1 w / v%.

  In the eyewash composition according to the present embodiment, the content ratio of the component (C) to the component (B) is not particularly limited, and the types of the components (B) and (C), and the types and contents of other compound components. It is set as appropriate according to the use and formulation of the eyewash composition. As the content ratio of the component (C) to the component (B), for example, from the viewpoint of further enhancing the effect of the present invention, the total content of the component (B) contained in the eyewash composition according to the present embodiment is 1% by mass. Parts, the total content of the component (C) is preferably 0.1 to 100 parts by mass, more preferably 1 to 80 parts by mass, and further preferably 5 to 50 parts by mass. preferable.

  In another aspect, the eyewash composition according to the present embodiment preferably contains a cooling agent. When the eyewash composition contains a cooling agent, the effect of enhancing the feeling of washing during eyewashing is more remarkably exhibited.

  Specific examples of the cooling agent include menthol, menthol, camphor, borneol, geraniol, cineol, citronellol, carvone, anethole, eugenol, limonene, linalool, linalyl acetate, thymol, cimene, terpineol, pinene, camphene, isoborneol, phenene Chen, nerol, myrcene, myrsenol, linalool acetate, lavandulol, eucalyptus oil, bergamot oil, peppermint oil, cool mint oil, spearmint oil, peppermint oil, fennel oil, cinnamon oil, rose oil, camphor oil. As a cooling agent, menthol, camphor, borneol, geraniol, eucalyptus oil, peppermint oil and peppermint oil are preferred, menthol, camphor, borneol and geraniol are more preferred, and menthol is even more preferred.

  A commercially available cooling agent may be used. One type of cooling agent may be used alone, or two or more types may be used in combination.

  The content of the cooling agent in the eyewash composition containing a cooling agent according to the present embodiment is not particularly limited, and the type of the cooling agent, the type and the content of other components, and the content of the eyewash composition It is set appropriately according to the use and the form of the preparation. As the content of the refreshing agent, from the viewpoint of more remarkably enhancing the effect of enhancing the feeling of washing during eye washing, for example, the total content of the cooling agent is 0.0001 to, based on the total amount of the eyewash composition. It is preferably 0.1 w / v%, more preferably 0.005 to 0.05 w / v%, even more preferably 0.001 to 0.03 w / v%.

  The pH of the eyewash composition containing a refreshing agent according to this embodiment is preferably from 5.0 to 8.5, and more preferably from 5.5 to 8.5, from the viewpoint of further enhancing the feeling of washing during eyewashing. 0, more preferably 5.0 to 7.5, still more preferably 5.0 to 7.0, particularly preferably 5.0 to 6.5. .

  The eyewash composition containing a cooling agent according to the present embodiment preferably contains a nonionic surfactant from the viewpoint of the stability of the cooling agent. When the eyewash composition containing a refreshing agent contains a nonionic surfactant, the effect of the present invention is more remarkably exhibited.

  Specific examples of the nonionic surfactant include POE (20) sorbitan monolaurate (polysorbate 20), POE (20) sorbitan monopalmitate (polysorbate 40), POE (20) monostearate sorbitan (polysorbate 60) and trisorbate. POE sorbitan fatty acid esters such as POE (20) sorbitan stearate (polysorbate 65), POE (20) sorbitan monooleate (polysorbate 80); POE (5) hydrogenated castor oil (polyoxyethylene hydrogenated castor oil 5), POE (10) hydrogenated castor oil (polyoxyethylene hydrogenated castor oil 10), POE (20) hydrogenated castor oil (polyoxyethylene hydrogenated castor oil 20), POE (30) hydrogenated castor oil (polyoxyethylene hydrogenated castor oil 30), POE (40) curing Castor oil (polyoxyethylene hydrogenated castor oil 40), POE (60) hydrogenated castor oil (polyoxyethylene hydrogenated castor oil 60), POE (80) hydrogenated castor oil (polyoxyethylene hydrogenated castor oil 80), POE (100) POE hardened castor oil such as hardened castor oil (polyoxyethylene hardened castor oil 100); POE (3) castor oil (polyoxyethylene castor oil 3), POE (10) castor oil (polyoxyethylene castor oil 10), POE (35) POE castor oil such as castor oil (polyoxyethylene castor oil 35), POE (70) castor oil (polyoxyethylene castor oil 70); POE (9) POE alkyl ether such as lauryl ether; POE (20) POE (4) POE-POP alkyl ether such as cetyl ether; POE (20) P P (20) glycol (Pluronic L44), POE (42) POP (67) glycol (Poloxamer 403, Pluronic P123), POE (54) POP (39) glycol (Poloxamer 235, Pluronic P85), POE (120) POP ( 40) Glycol (Pluronic F87), POE (160) POP (30) Glycol (Poloxamer 188, Pluronic F68), POE (196) POP (67) Glycol (Poloxamer 407, Pluronic F127), POE (200) POP (70) POE / POP glycols such as glycol; and polyethylene glycol monostearate such as polyoxyl stearate 10 and polyoxyl stearate 40. In the compounds exemplified above, the numbers in parentheses indicate the number of moles added. The abbreviation "POE" means polyoxyethylene, and the abbreviation "POP" means polyoxypropylene. As nonionic surfactants, POE sorbitan fatty acid esters, POE hydrogenated castor oil, POE castor oil, POE POP glycol, polyethylene glycol monostearate are preferred, and polysorbate 80, polyoxyethylene hydrogenated castor oil 60, and poloxamer 407 are preferred. More preferred are polysorbate 80 and polyoxyethylene hydrogenated castor oil 60.

  A commercially available nonionic surfactant may be used. As the nonionic surfactant, one type may be used alone, or two or more types may be used in combination.

  According to the present embodiment, the content of the nonionic surfactant in the eyewash composition containing a cooling agent and a nonionic surfactant is not particularly limited, the type of the nonionic surfactant, the other components It is appropriately set according to the type and content, the use of the eyewash composition, the formulation form, and the like. As the content of the nonionic surfactant, from the viewpoint of more remarkably improving the feeling of washing during eyewash, for example, based on the total amount of the eyewash composition, the total content of the nonionic surfactant is It is preferably from 0.01 to 10 w / v%, more preferably from 0.01 to 5 w / v%, even more preferably from 0.01 to 1 w / v%.

  In the eyewash composition containing a cooling agent and a nonionic surfactant according to this embodiment, the content ratio of the nonionic surfactant to the cooling agent is not particularly limited, and the cooling agent and the nonionic surfactant are used. It is appropriately set according to the type of agent, the type and content of other compounding components, the use of the eyewash composition and the form of formulation. As the content ratio of the content ratio of the nonionic surfactant to the cooling agent, from the viewpoint of further enhancing the effect of the present invention, for example, the total content of the cooling agent contained in the eyewash composition according to the present embodiment The total content of the nonionic surfactant is preferably 0.1 to 100 parts by mass, more preferably 1 to 80 parts by mass, and more preferably 5 to 50 parts by mass with respect to 1 part by mass. Is more preferable.

(Anti-inflammatory agent)
The eyewash composition according to the present embodiment preferably further contains an anti-inflammatory agent. When the eyewash composition further contains an anti-inflammatory agent, the effects of the present invention are more remarkably exhibited. Anti-inflammatory agents are compounds having an anti-inflammatory or anti-inflammatory effect, and salts thereof. The anti-inflammatory agent is not particularly limited as long as it is pharmaceutically, pharmacologically (pharmaceutically) or physiologically acceptable.

  Specific examples of anti-inflammatory agents include epsilon-aminocaproic acid, allantoin, berberine, azulene (azulene, azulene sulfonic acid, kama azulene, guaiazulene, etc.), glycyrrhizic acid, zinc salts (zinc sulfate, zinc lactate, etc.), lysozyme, celecoxib , Rofecoxib, indomethacin, diclofenac, bromfenac, piroxicam, meloxicam, methyl salicylate, ibuprofen, ibuprofen piconol, bufexamac, butyl flufenamic acid, bendazac, ketoprofen, felbinac, pranoprofen and salts thereof. As the anti-inflammatory agent, epsilon-aminocaproic acid and its salts, allantoin, berberine and its salts, azulene sulfonic acid and its salts, glycyrrhizic acid and its salts, and zinc salts are preferable, and epsilon-aminocaproic acid, allantoin, berberine chloride, and sulfuric acid Berberine, sodium azulene sulfonate, dipotassium glycyrrhizinate, zinc sulfate and zinc lactate are more preferred, and epsilon-aminocaproic acid, allantoin and dipotassium glycyrrhizinate are more preferred.

  A commercially available anti-inflammatory agent may be used. One type of anti-inflammatory agent may be used alone, or two or more types may be used in combination.

  The content of the anti-inflammatory agent in the eyewash composition according to the present embodiment is not particularly limited, and depends on the type of the anti-inflammatory agent, the type and content of the other components, the use of the eyewash composition, the formulation, and the like. Is set as appropriate. As the content of the anti-inflammatory agent, from the viewpoint of more remarkably exerting the effects of the present invention, for example, the total content of the anti-inflammatory agent is 0.00005 to 0.2 w / v%, more preferably 0.0001 to 0.1 w / v%, even more preferably 0.0004 to 0.55 w / v%.

(Water-soluble vitamin)
It is preferable that the eyewash composition according to the present embodiment further contains a water-soluble vitamin. When the eyewash composition further contains a water-soluble vitamin, the effect of the present invention is more remarkably exhibited. The water-soluble vitamin is not particularly limited as long as it is pharmaceutically, pharmacologically (pharmaceutically) or physiologically acceptable.

  Specific examples of the water-soluble vitamin include flavin adenine dinucleotide and salts thereof (flavin adenine dinucleotide sodium and the like), cobalamins (cyanocobalamin, methylcobalamin and the like), pyridoxine or a salt thereof (pyridoxine hydrochloride and the like), panthenol, pantothenic acid And salts thereof (eg, sodium pantothenate, potassium pantothenate, calcium pantothenate, magnesium pantothenate, etc.), pyridoxal and its salts (pyridoxal phosphate, etc.), ascorbic acid and its salts (sodium ascorbate, calcium ascorbate, etc.) Is mentioned. As the water-soluble vitamin, flavin adenine dinucleotide and its salt, cobalamin, pyridoxine or its salt, panthenol, pantothenic acid and its salt are preferable, and pyridoxine or its salt and panthenol are more preferable.

  Commercially available water-soluble vitamins may be used. One type of water-soluble vitamin may be used alone, or two or more types may be used in combination.

  The content of the water-soluble vitamin in the eyewash composition according to the present embodiment is not particularly limited, and depends on the type of the water-soluble vitamin, the type and content of other components, the use of the eyewash composition, the formulation, and the like. Is set as appropriate. As the content of the water-soluble vitamin, from the viewpoint of more remarkably exerting the effects of the present invention, for example, the total content of the water-soluble vitamin is 0.0001 to 0.1 w /, based on the total amount of the eyewash composition. v%, more preferably 0.0005 to 0.05 w / v%, even more preferably 0.0002 to 0.02 w / v%.

〔amino acid〕
The eyewash composition according to the present embodiment preferably further contains an amino acid. When the eyewash composition further contains an amino acid, the effect of the present invention is more remarkably exhibited. Amino acids are compounds having an amino group and a carboxyl group in the molecule, derivatives thereof, and salts thereof. The amino acid is not particularly limited as long as it is pharmaceutically, pharmacologically (pharmaceutically) or physiologically acceptable, and can be appropriately selected from known amino acids and used.

  Specific examples of amino acids include amino acids and their salts, amino acid derivatives and their salts, and mucopolysaccharides and their derivatives and their salts. Specific examples of amino acids and salts thereof include, for example, monoaminomonocarboxylic acids such as glycine, alanine, aminobutyric acid, and aminovaleric acid, monoaminodicarboxylic acids such as aspartic acid, and glutamic acid, diamino acids such as arginine, and lysine. Monocarboxylic acids, and salts thereof. Specific examples of amino acid derivatives and salts thereof include, for example, amino acid derivatives such as aminoethylsulfonic acid and salts thereof. Mucopolysaccharides and derivatives thereof and salts thereof include chondroitin sulfate and salts thereof. The amino acid may be any of D-form, L-form and DL-form. As the amino acid, monoaminodicarboxylic acid and its salt, amino acid derivative and its salt, mucopolysaccharide and its salt are preferable, aspartic acid and its salt, aminoethylsulfonic acid and its salt, chondroitin sulfate and its salt are more preferable, and asparagine Potassium acid, magnesium aspartate, magnesium / potassium aspartate (equivalent mixture), aminoethylsulfonic acid, and sodium chondroitin sulfate are more preferred, and potassium aspartate, aminoethylsulfonic acid, and sodium chondroitin sulfate are even more preferred.

  As the amino acid, a commercially available amino acid may be used. One amino acid may be used alone, or two or more amino acids may be used in combination.

  The content of the amino acid in the eyewash composition according to the present embodiment is not particularly limited, and is appropriately set according to the type of amino acid, the type and content of other components, the use of the eyewash composition, the formulation, and the like. You. From the viewpoint of more remarkably exerting the effects of the present invention, the content of the amino acid may be, for example, 0.0005 to 1 w / v% based on the total amount of the eyewash composition. Preferably, it is 0.001 to 0.5 w / v%, more preferably 0.005 to 0.3 w / v%.

(Buffer)
The eyewash composition according to the present embodiment preferably further contains a buffer. When the eyewash composition further contains a buffer, the effect of the present invention is more remarkably exhibited. The buffer is not particularly limited as long as it is pharmaceutically, pharmacologically (pharmaceutically) or physiologically acceptable.

  Examples of the buffer include an inorganic buffer which is a buffer derived from an inorganic acid, and an organic buffer which is a buffer derived from an organic acid or an organic base.

  Examples of the inorganic buffer include a borate buffer, a phosphate buffer, and a carbonate buffer. Examples of the borate buffer include boric acid or a salt thereof (such as an alkali metal borate and an alkaline earth metal borate). Examples of the phosphate buffer include phosphoric acid and salts thereof (eg, alkali metal phosphate and alkaline earth metal phosphate). Examples of the carbonate buffer include carbonic acid and salts thereof (eg, alkali metal carbonate and alkaline earth metal carbonate). Further, a borate, a phosphate or a carbonate hydrate may be used as the borate buffer, the phosphate buffer or the carbonate buffer. As more specific examples, boric acid or a salt thereof (sodium borate, potassium tetraborate, potassium metaborate, ammonium borate, borax, etc.) as a borate buffer; phosphoric acid or a salt thereof as a phosphate buffer Salts (disodium hydrogen phosphate, sodium dihydrogen phosphate, potassium dihydrogen phosphate, trisodium phosphate, tripotassium phosphate, calcium monohydrogen phosphate, calcium dihydrogen phosphate, etc.); Or salts thereof (sodium hydrogen carbonate, sodium carbonate, ammonium carbonate, potassium carbonate, calcium carbonate, potassium hydrogen carbonate, magnesium carbonate and the like).

  Examples of the organic buffer include a citrate buffer, an acetate buffer, a lactate buffer, a succinate buffer, a Tris buffer, an AMPD buffer and the like. Examples of the citrate buffer include citric acid and salts thereof (eg, alkali metal citrate and alkaline earth metal citrate). Examples of the acetic acid buffer include acetic acid or a salt thereof (eg, an alkali metal acetate, an alkaline earth metal acetate). Examples of the lactic acid buffer include lactic acid or a salt thereof (an alkali metal lactate, an alkaline earth metal lactate, and the like). Examples of the succinic acid buffer include succinic acid or a salt thereof (such as an alkali metal succinate). In addition, citrate, acetate, lactate or hydrate of succinate may be used as the citrate buffer, acetate buffer, lactate buffer or succinate buffer. As a more specific example, citric acid or a salt thereof (sodium citrate, potassium citrate, calcium citrate, sodium dihydrogen citrate, disodium citrate, etc.) as a citrate buffer; acetic acid as an acetate buffer Or a salt thereof (ammonium acetate, sodium acetate, potassium acetate, calcium acetate, etc.); lactic acid or a salt thereof (sodium lactate, potassium lactate, calcium lactate, etc.) as a lactic acid buffer; succinic acid or a salt thereof as a succinic acid buffer ( Monosodium succinate, disodium succinate, etc.). Examples of the Tris buffer include tromethamol or a salt thereof (tromethamol hydrochloride or the like). Examples of the AMPD buffer include 2-amino-2-methyl-1,3-propanediol or a salt thereof.

  Examples of the buffer include a borate buffer (for example, a combination of boric acid and borax), a phosphate buffer (for example, a combination of disodium hydrogen phosphate and sodium dihydrogen phosphate), and a tris buffer (for example, , Trometamol) are preferred, borate buffers are more preferred, boric acid and its salts are more preferred, and a combination of boric acid and borax is even more preferred.

  A commercially available buffer may be used. One type of buffer may be used alone, or two or more types may be used in combination.

  The content of the buffer in the eyewash composition according to the present embodiment is not particularly limited, and may be appropriately determined depending on the type of the buffer, the type and content of other components, the use of the eyewash composition, the formulation, and the like. Is set. As the content of the buffer, from the viewpoint of more remarkably exerting the effect of the present invention, for example, the total content of the buffer is 0.001 to 10 w / v% based on the total amount of the eyewash composition. Is preferably 0.1 to 5 w / v%, more preferably 0.5 to 3 w / v%.

  The eyewash composition according to the present embodiment can be adjusted to an osmotic pressure ratio within a range acceptable to a living body, if necessary. The appropriate osmotic pressure ratio can be appropriately set according to the use, formulation form, method of use, etc., of the eyewash composition, and can be, for example, 0.5 to 5.0, and 0.6 to 3.0. Is preferably set to 0.7 to 2.0, more preferably to 0.8 to 1.55. The osmotic pressure ratio is the ratio of the osmotic pressure of the sample to 286 mOsm (the osmotic pressure of a 0.9 w / v% aqueous sodium chloride solution) based on the 17th revised Japanese Pharmacopoeia. (Freezing point descent method). The standard solution for osmotic pressure ratio measurement (0.9 w / v% aqueous sodium chloride solution) was prepared by drying sodium chloride (Japanese Pharmacopoeia standard reagent) at 500 to 650 ° C. for 40 to 50 minutes and then in a desiccator (silica gel). After allowing to cool, 0.900 g thereof is accurately weighed and dissolved in purified water to prepare exactly 100 mL, or a commercially available standard solution for measuring osmotic pressure ratio (0.9 w / v% aqueous sodium chloride solution) can be used.

  The viscosity of the eyewash composition according to the present embodiment is not particularly limited as long as it is within a pharmaceutically, pharmacologically (pharmaceutically) or physiologically acceptable range. As the viscosity of the eyewash composition according to the present embodiment, for example, the viscosity at 20 ° C. measured with a rotational viscometer (RE550 type viscometer, manufactured by Toki Sangyo Co., Ltd .; rotor: 1 ° 34 ′ × R24) is 1 to 3. It is preferably 1,000 mPa · s, more preferably 1 to 100 mPa · s, still more preferably 1 to 50 mPa · s, still more preferably 1 to 30 mPa · s, and 1 to 10 mPa · s. s, particularly preferably 1 to 5 mPa · s.

The eyewash composition according to the present embodiment contains an appropriate amount of a combination of components selected from various pharmacologically active components and physiologically active components in addition to the above components as long as the effects of the present invention are not impaired. You may. The component is not particularly limited, and examples thereof include an active component in an ophthalmic drug described in the OTC Pharmaceutical Manufacturing and Marketing Approval Standards 2012 edition (supervised by the Society of Regulatory Science). Specific examples of the components used in ophthalmic drugs include the following components.
Antiallergic agents: for example, sodium cromoglycate, tranilast, potassium pemirolast and the like.
Steroids: For example, fluticasone propionate, fluticasone furoate, mometasone furoate, beclomethasone propionate, flunisolide and the like.
Decongestant: For example, tetrahydrozoline hydrochloride, tetrahydrozoline nitrate, naphazoline hydrochloride, naphazoline nitrate, epinephrine, epinephrine hydrochloride, ephedrine hydrochloride, phenylephrine hydrochloride, dl-methylephedrine hydrochloride and the like.
Ocular muscle modulators: for example, cholinesterase inhibitors having an active center similar to acetylcholine, such as neostigmine methyl sulfate, tropicamide, helenien, atropine sulfate and the like.
Inorganic salts: for example, chlorides of metals such as calcium chloride, magnesium chloride, sodium chloride, and potassium chloride; ammonium chloride; sulfates of metals such as calcium sulfate, magnesium sulfate, sodium sulfate, potassium sulfate, and ammonium sulfate.
Astringent: For example, zinc white.
Others: For example, sulfamethoxazole, sulfisoxazole, sulfisomidine, and salts thereof.

In the facial cleansing composition according to the present embodiment, various additives are appropriately selected according to a usual method, depending on the use and the form of the preparation, as long as the effects of the present invention are not impaired. An appropriate amount may be contained in combination with the above. Examples of such additives include various additives described in the Pharmaceutical Excipients Dictionary 2007 (edited by the Japan Pharmaceutical Excipients Association). Representative additives include the following additives.
Carrier: for example, an aqueous solvent such as water or hydrous ethanol.
Chelating agents: for example, ethylenediaminediacetic acid (EDDA), ethylenediaminetriacetic acid, ethylenediaminetetraacetic acid (EDTA), N- (2-hydroxyethyl) ethylenediaminetriacetic acid (HEDTA), diethylenetriaminepentaacetic acid (DTPA) and the like.
Base: for example, octyldodecanol, titanium oxide, potassium bromide, plastibase and the like.
Anionic surfactants: for example, polyoxyethylene alkyl ether phosphate, polyoxyethylene alkyl ether sulfate, alkylbenzene sulfonate, alkyl sulfate, N-acyl taurate and the like.
Amphoteric surfactants: for example, betaine lauryldimethylaminoacetate and the like.
Stabilizers: For example, sodium formaldehyde sulfoxylate (Rongalit), sodium bisulfite, sodium pyrosulfite, aluminum monostearate, glyceryl monostearate, cyclodextrin, monoethanolamine, dibutylhydroxytoluene, and the like.
Preservatives, bactericides or antibacterials: for example, zinc chloride, sodium benzoate, ethanol, chlorobutanol, sorbic acid, potassium sorbate, sodium dehydroacetate, methyl parahydroxybenzoate, ethyl paraoxybenzoate, propyl paraoxybenzoate, paraoxyl Butyl benzoate, oxyquinoline sulfate, phenethyl alcohol, benzyl alcohol, biguanide compounds (specifically, polyhexanide hydrochloride (polyhexamethylene biguanide), etc.), Gloquil (trade name, manufactured by Rhodia), chlorite, and the like.
Isotonizing agents: for example, sodium bisulfite, sodium sulfite, potassium chloride, calcium chloride, sodium chloride, magnesium chloride, potassium acetate, sodium acetate, sodium hydrogen carbonate, sodium carbonate, sodium thiosulfate, magnesium sulfate, glycerin, propylene glycol etc.
Thickeners: For example, cellulose-based polymer compounds (eg, methylcellulose, ethylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose, sodium carboxymethylcellulose, etc.), polyvinyl-based polymer compounds (polyvinylpyrrolidone, polyvinylalcohol, etc.), carboxyvinyl polymer, guar gum , Hydroxypropyl guar gum, gum arabic, gum karaya, xanthan gum, agar, alginic acid and its salts (such as sodium salt), mucopolysaccharides (for example, heparin-like substances, heparin, heparin sulfate, heparan sulfate, heparinoid, hyaluronic acid and its salts ( Sodium salts, etc.)), starch, chitin and its derivatives, chitosan and its derivatives, carrageenan and the like.
Saccharides: for example, glucose, cyclodextrin and the like.
Sugar alcohols: for example, xylitol, sorbitol, mannitol, glycerin and the like. These may be d-form, l-form or dl-form.

  When the eyewash composition according to the present embodiment contains water, as the content of water, from the viewpoint of more remarkably exerting the effects of the present invention, for example, based on the total amount of the eyewash composition, the water content The amount is preferably 80 w / v% or more and less than 100 w / v%, more preferably 85 w / v% or more and 99.5 w / v% or less, and 90 w / v% or more and 99.2 w / v% or less. Is more preferable.

  The water used in the eyewash composition according to the present embodiment may be pharmaceutically, pharmacologically (pharmaceutically) or physiologically acceptable. Examples of such water include distilled water, ordinary water, purified water, sterilized purified water, water for injection, and distilled water for injection. These definitions are based on the 17th revised Japanese Pharmacopoeia.

  The eyewash composition according to the present embodiment can be prepared, for example, by adding and mixing the component (A) and, if necessary, other components to a desired content. Specifically, for example, it can be prepared by dissolving or suspending the above components in purified water, adjusting the pH and osmotic pressure to predetermined values, and sterilizing by filtration sterilization or the like.

  The eyewash composition according to the present embodiment can take various forms depending on the purpose, and examples thereof include a liquid preparation, a gel preparation, and a semi-solid preparation (such as an ointment). Among these, liquid preparations are preferable, and aqueous preparations are more preferable.

  The eyewash composition according to the present embodiment can be applied while wearing a contact lens. The “contact lens” includes a hard contact lens and a soft contact lens (including both ionic and nonionic, and including both silicone hydrogel contact lenses and non-silicone hydrogel contact lenses). The eyewash composition according to the present embodiment is more preferably used while wearing a contact lens (preferably, a soft contact lens) since the effect of the present invention can be more remarkably exhibited.

  The number of times of administration of the eyewash composition according to the present embodiment per day is not particularly limited, and may be, for example, 1 to 12, 2 to 9, 3 to 6 times.

〔container〕
The eyewash composition according to the present embodiment is provided in an arbitrary container. The container may be a package having a portion (surface) that comes into contact with the eyewash composition. For example, the container may include a container body containing the eyewash composition, an inner stopper (nozzle) including an extraction port of the container, a cap, and the like. It may be configured. The material of the container is not particularly limited, and may be, for example, glass or plastic, but is preferably plastic from the viewpoint that the effects of the present invention are more remarkably exhibited.

  When the material of the container is plastic, specifically, for example, polyethylene terephthalate (PET), polybutylene terephthalate (PBT), polyethylene naphthalate, polyarylate, polycarbonate, polyethylene (PE; high density polyethylene (HDPE), low density Polyethylene (LDPE)), Polypropylene (PP), Polystyrene (PS), Acrylonitrile Butadiene Styrene (ABS), Polymethylpentene (PMP), Polyimide, and Copolymers of Monomers Constituting These, and Mixture of Two or More of These What was done. Among these, polyethylene (PE) is preferred. These plastics may contain additives such as stabilizers and reinforcing agents such as glass fibers.

  In the container, at least a part of a portion that comes into contact with the eyewash composition may be made of the above material. Here, the portion of the container that comes into contact with the eyewash composition includes, for example, the inner surface of the container main body (the innermost layer when the container has a structure including a plurality of layers) and an inner plug (nozzle). For example, when the container is a container having an inner stopper (nozzle), only the inner stopper (nozzle) may be formed of the above material (preferably polyethylene), and the container body other than the inner stopper (nozzle) may be formed of the above material. (Preferably polyethylene), and all of the portions in contact with the eyewash composition may be formed of the above-described material (preferably polyethylene). From the viewpoint that the effects of the present invention are more remarkably exhibited, it is preferable that the entire portion of the container that comes into contact with the eyewash composition is made of the above-mentioned material (preferably polyethylene).

  The type of the container is generally used in the field of ophthalmology, and is not particularly limited as long as the container can be used by dropping the contained eyewash composition.Specifically, for example, an inner stopper (Nozzle). The type of the container is preferably a container used as an ophthalmic container.

  The shape and capacity of the container are not particularly limited, and may be appropriately set according to the application. Further, the container may be a container in which a large number (for example, 25 times or more) of the amount of use of the eyewash composition is contained, and a small number of times (for example, 2 times or more and less than 25 times) of the use of the eyewash. It may be a container for accommodating the agent composition or a container for accommodating a single use amount of the eyewash composition.

  When the container contains a large number of (for example, 25 or more) usage amounts of the eyewash composition, for example, the volume may be 1 mL or more and 200 mL or less, and preferably 1 mL or more and 100 mL or less, More preferably, it is 1 mL or more and 50 mL or less. In the case where the container contains a small number of times (for example, 2 or more and less than 25 times) or a single use amount of the eyewash composition, for example, the volume may be 0.01 mL or more and 7 mL or less. It is preferably from 05 mL to 6 mL, more preferably from 0.1 mL to 5 mL, still more preferably from 0.1 mL to 3 mL, even more preferably from 0.2 mL to 2 mL, It is particularly preferable that the concentration be 0.2 mL or more and 1 mL or less. Further, the container may be a multi-dose type accommodating a plurality of usage amounts or a unit dose type accommodating a single usage amount.

  The container may be a container in which the container body and the spout are integrally formed. When the number of times of use is a small number (for example, 2 or more and less than 25 times) or a single container, and the capacity is 0.1 mL or more and 3 mL or less, the container is a container in which the container body and the spout are integrally formed. Is preferred.

  The eyewash composition according to the present embodiment can also be provided as a product (such as an eyewash) in which the eyewash composition is contained in a container.

  The eyewash composition according to the present embodiment can be used, for example, for washing eyes and preventing eye diseases (after swimming; when dust or sweat enters eyes).

  Hereinafter, the present invention will be specifically described based on test examples, but the present invention is not limited thereto.

[Test Example 1: Evaluation of cleaning effect on water-soluble foreign matter]
As a foreign substance, 10 μL of a 2% aqueous solution of trypan blue was instilled into Japanese white rabbits (3 kg or more, 16 to 18 weeks of age), and after eyewashing with eye drops or eyewashing using an eyecup according to the method described below, The cleaning effect was evaluated based on the amount of foreign substances washed out. In this test, a physiological saline solution was used as the eyewash composition.

In eye washing with eye drops, a normal eye drop container (capacity: 12 mL, made of polyethylene terephthalate resin) was used to drop 12 drops of physiological saline solution into one eye of each rabbit. The lower eyelid was lightly held down for every three drops, and the overflowing saline solution was collected using a pipette. The amount of each drop was about 40 μL.
In eye washing using an eye cup, using a normal eye cup (made of plastic), 5 mL of physiological saline is brought into contact with the cornea and bulbar conjunctiva of each rabbit once for 2 seconds for a total of 10 times. The saline solution was collected.
The amount of trypan blue washed out in the physiological saline solution was determined by the absorption spectrophotometry, and the recovery rate was calculated. Each test was performed six times, and the average value was determined.
The results are shown in FIG.

  As shown in FIG. 1, the recovery rate of trypan blue, which is a water-soluble foreign substance, was about 90% in eyewashing using an eyecup, whereas the recovery rate of trypan blue was about 75% in three drops in eyewashing with eye drops. %, About 90% with 6 drops, about 95% with 9 drops, and about 98% with 12 drops. These results indicate that the water-soluble foreign matter can be sufficiently removed by instilling 3 to 12 drops at a time.

[Test Example 2: Evaluation of cleaning effect on solid foreign matter]
200 polystyrene beads (particle size: 340 to 420 μm) suspended in 50 μL of 0.5% methylcellulose aqueous solution were used as foreign matter, and a normal ophthalmic container (capacity: 13 mL, made of polyethylene resin) was used as an ophthalmic container. The evaluation was performed in the same manner as in Test Example 1 except that the amount of dropping was about 50 μL per drop. The number of polystyrene beads was calculated from the dry weight. The results are shown in FIG.

  As shown in FIG. 2, the recovery rate of polystyrene beads, which are solid foreign substances, was about 80% in the eyewash using the eye cup, whereas the recovery rate of the polystyrene beads was about 65% for three drops in the eyewash using eye drops. And was about 80% at 6, 9, and 12 drops. These results show that solid foreign matter can be sufficiently removed by applying 3 to 12 drops per time.

[Test Example 3: Evaluation of cleaning effect on solid foreign matter when wearing soft contact lens]
Each eyewash composition shown in Table 1 was prepared by a conventional method.
A suspension of 50 polystyrene beads (340 to 420 μm) in 25 μL of 0.5% methylcellulose aqueous solution as foreign matter was instilled into Japanese white rabbits (3 kg or more, 16 to 18 weeks of age), and immediately thereafter, soft contact was performed. The lens was worn. Thereafter, using an ordinary eye dropper (made of polyethylene resin), 9 drops of the above prepared eyewash composition 1 or 2 was dropped on one eye of each rabbit. The lower eyelid was lightly held down every three drops, and the overflowing eyewash composition was collected using a pipette. The amount of each drop was about 40 μL. The number of polystyrene beads was calculated from the dry weight. The results are shown in FIG.

  As shown in FIG. 3, the recovery of polystyrene beads when using eyewash compositions 1 and 2 was about 75% and about 50% for 3 drops, respectively, and about 85% and about 70% for 6 drops, respectively. %, About 90% and about 80% respectively with 9 drops. These results show that even when wearing a soft contact lens, solid foreign matters can be sufficiently removed by applying 3 to 9 drops per time.

[Test Example 4: Evaluation of stability of chlorpheniramine maleate]
The eyewash compositions shown in Tables 2 and 3 were prepared by a conventional method. The unit of each component in Tables 2 and 3 is w / v%.
Each of the obtained eyewash compositions was filled into a unit dose container made of polyethylene resin, and the eyewash compositions shown in Table 2 were kept at 60 ° C. for 2 hours, and the eyewash compositions shown in Table 3 were kept at 60 ° C. for 3 hours. Let stand for days. Thereafter, chlorpheniramine maleate was quantified, and its residual ratio was determined. The stability improvement rate was determined based on the following equation.
Stability improvement rate (%) = [1− (100−residual rate of example) / (100−residual rate of control)] × 100
The results are shown in FIGS. 4 and 5, respectively.

  As shown in FIG. 4, the stability of chlorpheniramine maleate is improved by lowering the pH from 9.2, and the improvement rate is 30% or more at pH 8.3 or less and 50% at pH 8.0 or less. As described above, 70% or more at pH 7.5 or less, 85% or more at pH 7.0 or less, and 90% or more at pH 6.5 or less.

  Further, as shown in FIG. 5, the stability of chlorpheniramine maleate was improved by blending l-menthol, d-α-tocopherol acetate, and retinol palmitate, and the improvement rate was 20% or more. Met.

[Test Example 5: Evaluation of Effect of Cooling Agent on Washing Feeling During Eye Wash]
Each eyewash composition shown in Table 4 was prepared by a conventional method.
The effect of the cooling agent on the feeling of washing during eye washing was evaluated by the VAS (Visual Analog Scale) method. Specifically, five subjects instilled four drops each of the eyewash compositions 3 and 4 prepared above into the left and right eyes, and the left end of the 100-mm-long scale was evaluated as having 0 points of “no washing feeling”. The right end was designated as having a "feel of washing" of 100 points, and the degree of the feeling of washing felt by the subject was checked. In addition, the subject applied the eyewash composition in a state where the contact lens was not worn. The length from the zero point (left end) to the checked point was measured, and this length (mm) was taken as the washing feeling score. Thereafter, a t-test was performed on the washing feeling score of each eyewash composition. The results are shown in FIG.

  As shown in FIG. 6, the eyewash composition 4 containing l-menthol as a refreshing agent had a significantly higher washing feeling score than the eyewash composition 3 containing no refreshing agent. This result indicates that the cooling agent enhances the feeling of washing during eyewashing with eye drops.

(Prescription example)
Formulation examples are shown in Tables 5 and 6 below. The unit of each component in Tables 5 and 6 is w / v%. Formulation Examples 1 to 19 are all eyewashes, and the pH of Formulation Examples was adjusted with hydrochloric acid or sodium hydroxide as needed. Each of the prescription examples filled in a polyethylene container is referred to as prescription examples 1 ′ to 19 ′.

Claims (11)

  An eyewash composition for use in washing eyes by applying 3 to 12 drops at a time.   (A) It contains an antihistamine, the content of the component (A) is 0.00006 to 0.05 w / v% based on the total amount of the eyewash composition, and the pH is 5.0 to 8.5. The eyewash composition according to claim 1.   The eyewash composition according to claim 1 or 2, further comprising (B) a fat-soluble component, and (C) a nonionic surfactant.   The eyewash composition according to claim 3, wherein the component (B) is at least one selected from the group consisting of a cooling agent, vitamin E, vitamin A, and oil.   Component (C) is at least one selected from the group consisting of polyoxyethylene sorbitan fatty acid ester, polyoxyethylene hydrogenated castor oil, polyoxyethylene castor oil, polyoxyethylene polyoxypropylene glycol, and polyethylene glycol monostearate The eyewash composition according to claim 3, which is:   The eyewash composition according to claim 1, which contains a cooling agent and has a pH of 5.0 to 8.5.   The eyewash composition according to claim 6, wherein the cooling agent is at least one selected from the group consisting of menthol, camphor, borneol, and geraniol.   The eyewash composition according to claim 6, further comprising a nonionic surfactant.   The nonionic surfactant is at least one selected from the group consisting of polyoxyethylene sorbitan fatty acid ester, polyoxyethylene hydrogenated castor oil, polyoxyethylene castor oil, polyoxyethylene polyoxypropylene glycol, and polyethylene glycol monostearate. 9. The eyewash composition of claim 8, which is a seed.   The eyewash composition according to any one of claims 1 to 9, wherein the viscosity is 1 to 10 mPa · s. The eyewash composition according to any one of claims 1 to 10, wherein at least a part of a portion that comes into contact with the eyewash composition is contained in a container formed of polyethylene.

Images